心血管、肾脏与代谢(CVRM)
改善和挽救数百万慢性粒细胞增多症患者的生命.
Home / Our therapy areas /心血管、肾脏及代谢(CVRM)
澳门葡京赌博游戏致力于推进crvrm治疗
The impacts of CVRM diseases on people, 社会和澳门葡京赌博游戏的星球是巨大的和不断增长的, yet they remain underdiagnosed, 未被充分对待，它们之间的联系也未被充分认识.1-7 These conditions affect hundreds of millions of people around the world; we estimate that one in three people with a CVRM disease are living with two or more of these chronic diseases.8
Our ambition is to enhance care to improve outcomes for the millions of people who are living with the complexities of CVRM diseases, 及早干预以保护重要器官, slow or stop disease progression, 并有一天甚至治愈这些经常使人衰弱的疾病, 进行性和危及生命的疾病.1
通过了解这些条件之间的相互联系, we’re able to extend the use of our existing medicines and build one of the world’s broadest, deepest and strongest CVRM pipelines.9 By 2032, 澳门葡京赌博游戏的目标是在crvrm治疗方面领先世界, 帮助改变医疗实践的过程和范围.
crvrm疾病未满足的需求和流行情况
100s of millions
全球有60%的人患有慢性粒细胞白血病1
One in three
crvrm患者存在以上两种或两种以上的症状8
98%
2型糖尿病患者至少有一种其他的crvrm疾病10
40%–50%
心力衰竭患者有慢性肾脏疾病11
Our R&D approach
Scientific research is advancing our understanding of how CVRM diseases are interconnected. We are investing in a portfolio of next-generation therapeutics which are addressing multiple risk factors and tackling the underlying drivers of disease across cardiorenal and cardiometabolic diseases to improve health outcomes.
By combining pioneering science, digital technologies, 大数据和人工智能与人才的技能和经验, 澳门葡京赌博游戏的产品线超越了传统的小分子, monoclonal antibodies and peptides, to include nucleotide modalities such as antisense oligonucleotides and small interfering RNA, and novel gene and cell therapies 有可能使重要器官再生.
At the same time, 澳门葡京赌博游戏正在与世界领先的学者合作, non-governmental organisations (NGOs), biotech and other industry partners, healthcare professionals, 患者和决策者改善检测和诊断, streamline clinical trials, widen access, 让澳门葡京赌博游戏的药物更快地惠及更多的人.
ACT on CKD
ACT (Accelerate Change Together) on chronic kidney disease (CKD) is a programme by AstraZeneca to transform kidney health through partnerships aimed at reducing the proportion of patients progressing to kidney failure by 20% by 2025.
ACT on HF
At AstraZeneca, we believe we play a pivotal role in advancing the understanding of HF and driving better patient outcomes. 通过全球合作倡议, 澳门葡京赌博游戏的目标是减轻心衰患者的负担, healthcare systems and society.
Benevolent AI
As part of our approach to building knowledge from the masses of data to better understand disease biology, we have collaborated with BenevolentAI. In this collaboration, 澳门葡京赌博游戏正在结合澳门葡京赌博游戏在疾病领域的专业知识和大型, diverse datasets with BenevolentAI’s leading artificial intelligence and machine learning capabilities to build knowledge graphs for HF, CKD, idiopathic pulmonary fibrosis (IPF), and systemic lupus erythematosus.
Healthy Heart Africa
Our Healthy Heart Africa programme is committed to tackling hypertension and the increasing burden of cardiovascular disease (CVD) in Africa. Since launching in Kenya in 2014, 澳门葡京赌博游戏已经进行了超过1100万次血压检查, 检测到超过两百万的读数升高, trained over 5,800 healthcare workers, 启动了700多家医疗机构. In support of the United Nations targets to reduce the risk of premature death from NCDs, we aspire to reach 10 million people with elevated blood pressure across Africa by 2025.
Make the Change for Kidney Health
为肾脏健康做出改变汇集了患者组织, medical experts and industry to call on governments and policymakers to recognise chronic kidney disease (CKD) as an urgent global health priority and implement patient-centred and evidence-based policies that enable earlier detection, 诊断和立即获得护理和推荐治疗. 通过这样做，澳门葡京赌博游戏的目标是为患者带来最好的结果, healthcare systems, caregivers, the economy and the planet. This campaign is co-created with the Global Patient Alliance for Kidney Health as well as funded and produced by AstraZeneca.
Our people
Built on an impressive legacy in CVRM, we are uniquely positioned to build a healthier and longer future for people with CVRM diseases. 澳门葡京赌博游戏超过1000人的团队跨越了23个功能，包括早期和晚期R&D, medical and commercial.
澳门葡京赌博游戏的员工都是有成就和经验丰富的科学家, researchers, clinicians, and healthcare and commercial professionals dedicated to advancing novel science and driving practice change to benefit patients with CVRM diseases.
The CVRM team is led by:
Join our team
Join and help us address CVRM diseases. Our teams are based across the globe, with core hubs in Cambridge, Gaithersburg, Wilmington and Gothenburg. 澳门葡京赌博游戏很自豪能够培养一种不断探索的文化, 质疑和挑战寻找不同的做事方法, 并对病人的生活产生积极的影响.
Our medicines
澳门葡京赌博游戏无法在本网站上提供澳门葡京赌博游戏处方药的详细信息, in compliance with regulations. Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, healthcare professionals and patients can visit local AstraZeneca websites to find out more about our medicines. 请注意，在一些国家，澳门葡京赌博游戏不允许提供太多, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. 一定要向医疗保健专业人员咨询有关药物的建议.
Our pipeline for CVRM
With more than 25 therapies and therapy combinations in our early-to-late stage pipeline, we seek to bring real science and development to combatting life-threatening conditions. Our first-class scientific research today is setting the stage for our pioneering approach in the fields of disease regression and organ regeneration, 让澳门葡京赌博游戏离把科幻小说变成现实又近了一步.
第三阶段/LCM项目:指的是第二/第三阶段的关键资产, 或者已经提交监管部门批准的, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets).
References
1. Vos T, et al. 204个国家和地区的369种疾病和伤害的全球负担, 1990-2019: 2019年全球疾病负担研究的系统分析. Lancet. 2020;396(10258):1204-22
2. Sarnak MJ, et al. 慢性肾脏疾病和冠状动脉疾病:JACC最新进展综述. J Am Coll Cardiol. 2019;74(14):1823-38.
3. Tourki B, et al. Heart Failure Syndrome With Preserved Ejection Fraction Is a Metabolic Cluster of Non-resolving Inflammation in Obesity. Front Cardiovasc Med. 2021;8:695952.
4. Rangaswami J, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, 和治疗策略:美国心脏协会的科学声明. Circulation. 2019;139(16):e840-e78.
5. Vogel B, et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet. 2021;397(10292):2385-438.
6. Carpio E , et al. Hypertension and cardiovascular risk factor management in a multi-ethnic cohort of adults with CKD: a cross sectional study in general practice. J Nephrol. 2022;35(3):901-10
7. Virani SS, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020;141(9):e139-e596.
8. AstraZeneca Data on File. REF-200649
9. AstraZeneca [Internet]. Our pipeline. [cited 2023 May 25]. Available from: http://xr.softqatest.net/our-therapy-areas/pipeline.html
10. Iglay K, Hannachi H, Joseph Howie P，等. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. Jul 2016;32(7):1243-52. doi:10.1185/03007995.2016.1168291
11. Vijay K, et al. Heart Failure in Patients with Diabetes and Chronic Kidney Disease: Challenges and Opportunities. Cardiorenal Med. (2022) 12 (1): 1–10.
Veeva ID: Z4-62672
Date of preparation: March 2024